Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Anyang-si
Clinical trial register · South Korea

Clinical Trials in Anyang-si, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca10 Eli Lilly and Company4 Seoul National University Hospital3 Janssen Research & Development, LLC3 Sanofi2
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Anyang-si

52 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Eli Lilly and Company
Phase 3
2,001
Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam
2026-08-26
Recruiting
AstraZeneca
Phase 3
7,000
Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul
2026-08-21
Not yet open
Seoul National University Hospital
Not applicable
2,301
Chuncheon, Gangneung, Anyang-si, Bucheon-si, Goyang-si, Changwon, Busan, Daegu
2026-06-15
Recruiting
Pfizer
Phase 3
954
Daejeon, Anyang-si, Yangsan, Incheon, Seoul
2026-06-10
Recruiting
Jade Biosciences, Inc.
Phase 2
30
Anyang-si, Seongnam-si, Seoul, Suwon
2026-05-19
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Wŏnju, Anyang-si, Seongnam-si, Suwon, Uijeongbu-si, Yangsan, Daegu, Daejeon
2026-05-11
Recruiting
Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke)
NCT07687706Ischemic Stroke, Ischemic Stroke, Acute, Transient Ischemic Attack (TIA), Cerebrovascular Disease
DrugTegoprazan
Hanyang University Guri Hospital
Phase 3
1,524
Busan, Daegu, Chuncheon, Anyang-si, Iksan, Jeonju, Cheongju-si, Guri-si
2026-01-26
Recruiting
Regeneron Pharmaceuticals
Phase 1
90
Anyang-si, Seoul
2025-12-22
Recruiting
Generate Biomedicines
Phase 3
786
Busan, Anyang-si, Seoul
2025-12-03
Recruiting
UCB Biopharma SRL
Phase 3
320
Anyang-si, Bucheon-si, Busan, Gwangju, Jeonju, Seongnam-si, Seoul
2025-11-14
Recruiting
AstraZeneca
Phase 2
435
Anyang-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Ulsan
2025-11-06
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Anyang-si, Seoul, Yongin-si
2025-09-30
Recruiting
Eli Lilly and Company
Phase 3
1,000
Anyang-si, Bucheon-si, Busan, Gwangju, Junggu, Seoul
2025-09-30
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Anyang-si, Busan, Changwon-si, Cheongju-si, Daegu, Daejeon, Goyang-si, Gwangju
2025-09-22
Recruiting
Sanofi
Phase 4
218
Anyang-si, Seoul
2025-09-22
Recruiting
Sanofi
Phase 3
942
Anyang-si, Daegu, Jeonju, Seoul
2025-09-17
Recruiting
AstraZeneca
Phase 2
987
Anyang-si, Cheongju-si, Chuncheon, Daegu, Jeonju, Seongnam-si, Seoul, Wŏnju
2025-06-27
Active, closed
AstraZeneca
Phase 3
3,103
Anyang-si, Bucheon-si, Busan, Changwon-si, Cheonan-si, Daegu, Daejeon, Gangwon-do
2025-05-28
Recruiting
Biogen
Phase 3
454
Busan, Anyang-si, Seongnam-si, Suwon, Seoul
2025-05-08
Recruiting
AstraZeneca
Phase 3
990
Anyang-si, Daegu, Iksan-si, Jeonju, Seoul, Uijeongbu-si, Wŏnju
2025-03-18
Recruiting
Seoul National University Hospital
Phase 2
100
Gangneung, Anyang-si, Ilsan, Seongnam-si, Seoul
2025-03-11
Recruiting
AstraZeneca
Phase 3
5,000
Ansan-si, Anyang-si, Busan, Cheonan-si, Goyang-si, Gwangju, Seongnam-si, Seoul
2025-03-03
Active, closed
argenx
Phase 3
631
Anyang-si, Suwon, Gwangju, Seoul
2025-01-15
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Seogu, Gwangju, Anyang-si, Seongnam-si, Seoul
2025-01-08
Active, closed
Sanofi Pasteur, a Sanofi Company
Phase 3
1,714
Busan, Daegu, Gwangju, Ansan-si, Anyang-si, Bucheon-si, Hwaseong-si, Seongnam-si
2024-12-18
Active, closed
Il-Yang Pharm. Co., Ltd.
Observational
169
Anyang-si, Daegu
2024-10-24
Recruiting
Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment
NCT06618638ADPKD (autosomal Dominant Polycystic Kidney Disease)
Seoul National University Hospital
Not applicable
340
Anyang-si, Seoul, Busan, Daegu, Gwangju
2024-10-21
Recruiting
CSL Behring
Phase 2/3
3,110
Ilsan-gu, Anyang-si, Daegu, Gangnam-gu, Goyang-si, Guri-si, Gwangju, Seoul
2024-04-27
Recruiting
AstraZeneca
Phase 3
3,850
Anyang-si, Bucheon-si, Busan, Cheongju-si, Daegu, Daejeon, Gwangju, Gwangmyeong
2024-04-12
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Anyang-si, Busan, Deagu, Gwangju, Gyeonggi-do, Seoul, Suwon
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul
2024-03-29
Recruiting
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1/2
180
Uijeongbu-si, Anyang-si, Busan, Daegu
2024-03-26
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Ansan-si, Anyang-si, Bucheon-si, Gwangju, Seongnam, Seoul
2024-03-09
Recruiting
AstraZeneca
Phase 3
5,250
Anyang-si, Busan, Daegu, Gwangju, Jeonju, Seoul, Uijeongbu-si, Ulsan
2024-02-21
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Yangsan, Jeonju, Hwasun-gun
2024-01-10
Active, closed
Hoffmann-La Roche
Phase 3
459
Anyang-si, Bucheon-si, Cheongju-si, Gyeonggi-do, Seongnam-si, Seoul
2023-08-08
Recruiting
Asciminib RMP Study
NCT05943522Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Observational
600
Wŏnju, Anyang-si, Bucheon-si, Uijeongbu-si, Gyeonggi-do, Incheon, Seoul, Suwon
2023-07-19
Active, closed
AstraZeneca
Phase 2
60
Anyang-si, Busan, Daegu, Seoul
2023-07-18
Active, closed
Alumis Inc
Phase 2
408
Anyang-si, Busan, Seoul
2023-06-26
Active, closed
Eli Lilly and Company
Phase 3
3,127
Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu
2023-06-05
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Anyang-si, Busan, Cheonan-si, Cheongju-si, Chuncheon, Daegu, Daejeon, Goyang-si
2023-04-11
Active, closed
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugPovetacicept
Alpine Immune Sciences, Inc.
Phase 1/2
72
Cheonan, Anyang-si, Goyang-si, Guri-si, Seoul, Suwon
2023-03-15
Active, closed
Janssen Research & Development, LLC
Phase 3
12,523
Anyang-si, Busan, Daegu, Daejeon, Goyang-si, Gwangju, Incheon, Jeju Special
2023-02-15
Active, closed
Areteia Therapeutics
Phase 3
600
Anyang-si, Bucheon-si, Busan, Gwangju, Incheon, Jeonju, Seoul, Suwon
2023-01-30
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Anyang-si, Busan, Daegu, Daejeon, Goyang-si, Gwangju, Gyeonggi-do, Seongnam-si
2022-12-27
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Anyang-si, Busan, Daegu, Goyang-si, Incheon, Seongnam-si, Seoul
2021-12-02
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 3
626
Busan, Anyang-si, Goyang-si, Seongnam-si, Suwon, Daegu, Yangsan, Jeonju
2021-11-05
Active, closed
Mirati Therapeutics Inc.
Phase 3
461
Anyang-si, Busan, Daejeon, Goyang-si, Hwasun-gun, Seongnam-si, Seoul, Suwon
2021-06-24
Active, closed
Atrasentan in Patients With Proteinuric Glomerular Diseases
NCT04573920IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
DrugAtrasentan
Novartis Pharmaceuticals
Phase 2
103
Cheonan, Anyang-si, Seoul
2021-03-15
Active, closed
Travere Therapeutics, Inc.
Phase 3
406
Seongnam-si, Anyang-si, Busan, Incheon, Seoul
2018-12-11
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Dongan, Seoul, Anyang-si, Goyang-si, Daegu, Gwangju, Gyeonggi-do, Jeju-do
2013-03-18
Rows per page Showing 1–52 of 52
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/anyang-si

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 52 of those studies with a site in Anyang-si.

How many clinical trials are recruiting in Anyang-si?

29 of the 52 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 22 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Anyang-si), 52 studies
PhaseStudiesRecruitingShare
Phase 3331763.5%
Phase 28415.4%
Observational325.8%
Not applicable213.8%
Phase 1/2213.8%
Phase 2/3223.8%
Phase 1111.9%
Phase 4111.9%

Most active sponsors

Lead sponsors with the most studies (Anyang-si)
Lead sponsorStudiesRecruiting
AstraZeneca107
Eli Lilly and Company43
Janssen Research & Development, LLC30
Seoul National University Hospital32
Alexion Pharmaceuticals, Inc.21
Alumis Inc20
Novartis Pharmaceuticals21
Ono Pharmaceutical Co., Ltd.20
Sanofi22
Alnylam Pharmaceuticals11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.